Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
|Articles|November 5, 2021
November 2021: In this Issue
Author(s)Lindsey Carr, Editor
As always, this month’s edition of Contemporary OB/GYN® features multiple peer-reviewed articles that offer in-depth guidance and analyses of key topics in ob/gyn. Here are the highlights of this special technology-centered issue.
Advertisement
Advertisement
Related to this article
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
Neurokinin receptor antagonists improve menopausal sleep disturbance
3
Stephanie Faubion, MD, on the first menopause therapy discussion
4
Brain fog at menopause: Separating normal change from dementia
5